How many drugs treat Bronchospasm Prevention?

Drug Landscape tracks 9 marketed treatments for Bronchospasm Prevention (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/bronchospasm-prevention.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Bronchospasm Prevention — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Bronchospasm Prevention (disease) competitive landscape: 9 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

9 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Bronchospasm Prevention, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Xopenex	LEVOSALBUTAMOL	Oak Pharms Inc	beta2-Adrenergic Agonist	Beta-2 adrenergic receptor	1999-01-01
Tornalate	BITOLTEROL	Sanofi	bitolterol	Beta-2 adrenergic receptor	1984-01-01
ProAir	albuterol	Generic (originally Allen & Hanburys/GSK)	SABA (Short-acting beta-2 agonist)	Beta-1 adrenergic receptor, Beta-2 adrenergic receptor, Beta-2 adrenergic receptor	1982-05-05
Intal	cromoglicic acid	Pfizer	Mast Cell Stabilizer	G-protein coupled receptor 35	1982-01-01
Proventil	salbutamol	Merck & Co.	beta2-Adrenergic Agonist	Beta-2 adrenergic receptor	1981-01-01
Levalbuterol	Levalbuterol	University of Aleppo		beta 2 -adrenergic receptors
xopenex	xopenex	Phoenix Children's Hospital		Beta-2 adrenergic receptor
Cromoglycate	Cromoglycate	Vishwajit Nimgaonkar, MD PhD		Protein S100-P, G-protein coupled receptor 35, Taste receptor type 2 member 20
Cromoglicate	Cromoglicate	LEO Pharma		Protein S100-P, G-protein coupled receptor 35, Taste receptor type 2 member 20

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 2 drugs in Bronchospasm Prevention
Generic (originally Allen & Hanburys/GSK) · 1 drug in Bronchospasm Prevention
LEO Pharma · 1 drug in Bronchospasm Prevention
Merck & Co. · 1 drug in Bronchospasm Prevention
Oak Pharms Inc · 1 drug in Bronchospasm Prevention
Pfizer · 1 drug in Bronchospasm Prevention
Phoenix Children's Hospital · 1 drug in Bronchospasm Prevention
Sanofi · 1 drug in Bronchospasm Prevention
University of Aleppo · 1 drug in Bronchospasm Prevention
Vishwajit Nimgaonkar, MD PhD · 1 drug in Bronchospasm Prevention

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Bronchospasm Prevention:

Cite this brief

Drug Landscape (2026). Bronchospasm Prevention — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/bronchospasm-prevention. Accessed 2026-06-10.

Bronchospasm Prevention full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing